Skip to main content
OpenTrials
Recruiting

NCT Number: NCT04217512

Pantoprazole in Cisplatin Nephrotoxicity

Pantoprazole in Cisplatin Nephrotoxicity

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Oncology Neoplasms

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

About this study

Pantoprazole in Cisplatin NephrotoxicityPantoprazole in Cisplatin Nephrotoxicity. Is it protective?

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with head and neck cancer

Exclusion criteria

  • GFR less than 59.
  • DM
  • Elevated liver enzymes more than 3 fold.

Treatment and study plan

Pantoprazole low dose

Drug

Pantoprazole 0.6 mg/kg

Other names: zurcal

Pantoprazole high dose

Drug

Pantoprazole 1.6 mg\\kg

Other names: zurcal, Controloc

Standard Hydration

Other

Standard hydration alone

Other names: Hydration

Cisplatin

Drug

Cisplatin

Primary outcomes

  1. Number of patients with no renal toxicity

    Time frame: 6 months

    The number of patients with no renal toxicity

Study contacts

Contact information is provided by the study sponsor or research team.

Sherief Abd-Elsalam, ass. prof.

CONTACT

[email protected]

00201147773440

Sponsors and collaborators

Lead sponsor

Sherief Abd-Elsalam

Other

Registry information

Official study title

Possible Protective Effect of Pantoprazole in Cisplatin Induced Nephrotoxicity in Patients With Head and Neck Cancer

Important dates

Study start
2019
Primary completion
2030
Study completion
2030
First posted
Jan 3, 2020
Registry last updated
Jan 3, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.